Robert H. Lurie Comprehensive Cancer Center

AccessHope Honored as Winner of the 2023 Well-Being Trailblazer Award

Retrieved on: 
Thursday, July 20, 2023
Well, NAACP Theatre Award – Trailblazer Award, Organization, National Cancer Institute, Cancer, NCI, Archetype, Physician, Robert H. Lurie Comprehensive Cancer Center, Nursing

DUARTE, Calif., July 20, 2023 /PRNewswire/ -- AccessHope, LLC , a company changing the way cancer expertise is delivered, is proud to announce its recognition as a winner of the esteemed 2023 Well-Being Trailblazer Award .

Key Points: 
  • DUARTE, Calif., July 20, 2023 /PRNewswire/ -- AccessHope, LLC , a company changing the way cancer expertise is delivered, is proud to announce its recognition as a winner of the esteemed 2023 Well-Being Trailblazer Award .
  • Presented by Archetype and the Wellness Council of America (WELCOA) , this prestigious award celebrates AccessHope's contributions to the well-being industry and its commitment to transforming workplace wellness.
  • "As employers seek ways to improve cancer care for their employees while managing costs, they need a trusted partner that enables access to leading cancer expertise," said AccessHope CEO Mark Stadler.
  • Presented by Archetype and the Wellness Council of America (WELCOA), the Well-Being Trailblazer Awards celebrate innovative companies reshaping workplace wellness.

The Caris Precision Oncology Alliance Welcomes Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Retrieved on: 
Tuesday, May 16, 2023
News, Database, Robert H. Lurie Comprehensive Cancer Center, Hospital, FACP, NCI-designated Cancer Center, National Cancer Institute, Intelligence, National Comprehensive Cancer Network, MBA, Research, U.S. News & World Report, POA, Patient, Physician, Machine learning, Medicine, Northwestern Memorial Hospital, Northwestern University Pritzker School of Law, Nursing, Medical imaging, Cancer

IRVING, Texas, May 16, 2023 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced today that Robert H. Lurie Comprehensive Cancer Center of Northwestern University has joined the Caris Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research, with its members working together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients. POA members are uniquely positioned to leverage Caris' highly sophisticated AI bioinformatics and machine learning capabilities across the company's massive clinico-genomic database to enable innovative research to improve clinical outcomes for cancer patients.

Key Points: 
  • IRVING, Texas, May 16, 2023 /PRNewswire/ -- Caris Life Sciences ®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced today that Robert H. Lurie Comprehensive Cancer Center of Northwestern University has joined the Caris Precision Oncology Alliance™ (POA).
  • As a National Cancer Institute-designated Comprehensive Cancer Center and founding member of the National Comprehensive Cancer Network, Lurie Cancer Center is leading efforts to improve cancer prevention, detection, and care.
  • "We are thrilled that Northwestern University's Lurie Cancer Center has joined the ever-expanding Caris Precision Oncology Alliance network," said Chadi Nabhan , M.D., MBA, FACP, Chairman of the Caris Precision Oncology Alliance.
  • "The vision of the Caris Precision Oncology Alliance is aligned with that of Lurie Cancer Center in bringing cutting edge technologies and therapies to all patients diagnosed with cancer."

Illinois Biotechnology Innovation Organization Appoints Three Industry Leaders to Board of Directors

Retrieved on: 
Tuesday, October 18, 2022
Marketing, Allergan, AstraZeneca, Time, Therapy, Baxalta, Clinical professor, Growth, MS, Head, Politics, AbbVie, Colorectal Cancer Alliance, Education, Robert H. Lurie Comprehensive Cancer Center, Champaign County, Illinois, MBA, Research, Mayo Clinic, Piper Sandler Companies, University, Colorectal cancer, Baxter, Industry, Bristol Myers Squibb, Rosalind Franklin University of Medicine and Science, CEO, M&A, International business, Association, Astellas Pharma, Takeda Pharmaceutical Company, United Kingdom, University of Warwick Science Park, Tennant, Notre Dame, Baxter International, Management, Pharmaceutical industry, Merck, Searle, Horizon, Northwestern University, Whalen, Biotechnology

CHICAGO, Oct. 18, 2022 /PRNewswire/ -- The Illinois Biotechnology Innovation Organization (iBIO), the trade association that represents the 88,000 jobs in Illinois' life sciences sector, today announced the addition of three new members to its board of directors: Rahul Jerath, senior director, head of Oncology Business Development & Acquisitions at AbbVie; Phil Tennant, senior vice president and head of Oncology Business Unit at Astellas Pharma, Inc.; and Joe Whalen, senior vice president, Alliances & International Business Development at Horizon Therapeutics."As the Illinois life sciences community experiences unprecedented growth, now is a particularly exciting time to leverage the rich experience and insights of Joe, Rahul and Phil," said John Conrad, iBIO president and CEO. "Each of these new board members brings unique perspectives to our advocacy, community building and education efforts. I look forward to working together as we foster more industry growth in Illinois."

Key Points: 
  • "Each of these new board members brings unique perspectives to our advocacy, community building and education efforts.
  • I look forward to working together as we foster more industry growth in Illinois."
  • With the addition of Whalen, Tennant and Jerath, the iBIO board of directors has 21 members.
  • The Illinois Biotechnology Innovation Organization (iBIO) is a life sciences industry association that represents the 88,000 life sciences employees in Illinois.

NCCN's New Patient Guidelines for Marginal Zone Lymphoma Help Patients and Caregivers Better Understand a Rare Form of Blood Cancer

Retrieved on: 
Monday, September 12, 2022
Lymph, Breast, Policy, Blood, Infection, Patient, National Comprehensive Cancer Network, Strathcona County, Research, CAR, COVID-19, Lymphatic system, Incidence, Person, Bone marrow, Doctor of Philosophy, Journal of the National Comprehensive Cancer Network, Skin, Spleen, NCCN, Stomach, Decision-making, Robert H. Lurie Comprehensive Cancer Center, Lymphoma, Health, Memorial Sloan Kettering Cancer Center, Feinberg School of Medicine, Twitter, Prostate, Immunotherapy, Cancer, Pathology, Diagnosis, PMID, Caregiver, Lung, Awareness, Education, Toxicity, Vaccine, Pharmaceutical industry, Medical device, Medicine, Amazon, MD, B-cell lymphoma

PLYMOUTH MEETING, Pa., Sept. 12, 2022 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) has published new NCCN Guidelines for Patients®: Marginal Zone Lymphoma. A cancer of the lymphatic system, marginal zone lymphoma (MZL) is a type of non-Hodgkin B-cell lymphoma that is typically slow-growing, and comprises about 8% of non-Hodgkin lymphoma cases1.

Key Points: 
  • A cancer of the lymphatic system, marginal zone lymphoma (MZL) is a type of non-Hodgkin B-cell lymphoma that is typically slow-growing, and comprises about 8% of non-Hodgkin lymphoma cases1.
  • The patient guidelines for Marginal Zone Lymphoma guidelines are the latest in NCCN's library of NCCN Guidelines for Patients , published through funding from the NCCN Foundation and available online free of charge.
  • NCCN Guidelines for Patients are available for free online at NCCN.org/patientguidelines and via the NCCN Patient Guides for Cancer App .
  • The NCCN Guidelines for Patients provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation .

NCCN's New Patient Guidelines for Marginal Zone Lymphoma Help Patients and Caregivers Better Understand a Rare Form of Blood Cancer

Retrieved on: 
Monday, September 12, 2022
Lymph, Breast, Policy, Blood, Infection, Patient, National Comprehensive Cancer Network, Strathcona County, Research, CAR, COVID-19, Lymphatic system, Incidence, Person, Bone marrow, Doctor of Philosophy, Journal of the National Comprehensive Cancer Network, Skin, Spleen, NCCN, Stomach, Decision-making, Robert H. Lurie Comprehensive Cancer Center, Lymphoma, Health, Memorial Sloan Kettering Cancer Center, Feinberg School of Medicine, Twitter, Prostate, Immunotherapy, Cancer, Pathology, Diagnosis, PMID, Caregiver, Lung, Awareness, Education, Toxicity, Vaccine, Pharmaceutical industry, Medical device, Medicine, Amazon, MD, B-cell lymphoma

PLYMOUTH MEETING, Pa., Sept. 12, 2022 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) has published new NCCN Guidelines for Patients®: Marginal Zone Lymphoma. A cancer of the lymphatic system, marginal zone lymphoma (MZL) is a type of non-Hodgkin B-cell lymphoma that is typically slow-growing, and comprises about 8% of non-Hodgkin lymphoma cases1.

Key Points: 
  • A cancer of the lymphatic system, marginal zone lymphoma (MZL) is a type of non-Hodgkin B-cell lymphoma that is typically slow-growing, and comprises about 8% of non-Hodgkin lymphoma cases1.
  • The patient guidelines for Marginal Zone Lymphoma guidelines are the latest in NCCN's library of NCCN Guidelines for Patients , published through funding from the NCCN Foundation and available online free of charge.
  • NCCN Guidelines for Patients are available for free online at NCCN.org/patientguidelines and via the NCCN Patient Guides for Cancer App .
  • The NCCN Guidelines for Patients provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation .

Envisagenics is Awarded Another SBIR Grant From the National Cancer Institute to Commercialize its AI/ML Platform for Immunotherapy Development

Retrieved on: 
Tuesday, August 2, 2022
National, Algorithm, NIH, RNA splicing, Research associate, Genome, Small Business Innovation Research, Neurodegeneration, Research, SBIR, IO, National Institute, Artificial intelligence, National Institute of General Medical Sciences, Risk, National Cancer Institute, Robert H. Lurie Comprehensive Cancer Center, Machine learning, Biotechnology, Disease, Cold, Patient, Breast cancer, NIGMS, Therapy, Feinberg School of Medicine, RNA-Seq, Breast, Lists of diseases, Cold Spring Harbor Laboratory, RNA, NCI, Pharmaceutical industry, Vaccine, Cancer

This grant will provide $2 million over 2 years to commercialize Envisagenics' proprietary drug discovery platform, SpliceIOTM, for the discovery of novel targets for immuno-oncology (IO) therapeutic development.

Key Points: 
  • This grant will provide $2 million over 2 years to commercialize Envisagenics' proprietary drug discovery platform, SpliceIOTM, for the discovery of novel targets for immuno-oncology (IO) therapeutic development.
  • Envisagenics was previously awarded Phase I and Phase II grants from the National Institute of General Medical Sciences (NIGMS, NIH) to develop the SpliceCore software platform.
  • A Phase I SBIR grant was also awarded by the NCI to expand SpliceCore's capabilities for discovery of splicing-derived neoantigens.
  • Envisagenics is a spin-out of Cold Spring Harbor Laboratory and a proud woman- and minority-led recipient of several grants from the National Institute of General Medical Sciences and the National Cancer Institute.